Merck KGaA's French Subsidiary Indicted in France Over Drug Formulation Change
October 19 2022 - 9:58AM
Dow Jones News
By Cecilia Butini
Merck KGaA's French subsidiary was indicted by a judge in the
French city of Marseille after complaints were filed against a
change in formulation of a thyroid drug it produces.
The German pharmaceutical and technology company said that the
investigation is about the information received by patients on the
formulation change of the drug, which is named Levothyrox. It is
"not linked to the quality of the new formulation," it said.
The change was prompted by a 2012 request from French
authorities, which required companies making thyroid treatments to
tighten specifications for levothyroxine sodium content in order to
improve the stability of the drug, according to Merck. The new
formulation is approved in more than 40 countries, it said.
The company said it is cooperating fully with the justice
system.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 19, 2022 09:43 ET (13:43 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From May 2024 to Jun 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Jun 2023 to Jun 2024
